Induction and Maintenance Therapy for Collagenous Colitis

Induction Therapy

Budesonide 9 mg once daily for 6–8 weeks is the first‑line induction regimen, achieving clinical remission in significantly more patients than no treatment (relative risk 2.52; 95 % CI 1.45–4.4). Strong evidence. 1, 2
Clinical improvement with budesonide typically begins within 7–13 days of starting therapy. Strong evidence. 1
Budesonide is well tolerated, with a low incidence of serious adverse events and convenient once‑daily dosing. Strong evidence. 1
Budesonide is superior to mesalamine (9 mg budesonide vs 3 g mesalamine daily), nearly doubling the likelihood of achieving both clinical and histological remission. Strong evidence. 1, 2

Mesalamine 3 g daily may be used as a second‑line agent; this is a conditional recommendation based on moderate‑quality evidence. 1
Bismuth subsalicylate (nine 262 mg tablets daily for 8 weeks) is a third‑line option; conditional recommendation with low‑quality evidence. 3
Prednisone or prednisolone can be considered as a fourth‑line alternative, particularly when cost is a barrier; conditional recommendation with very low‑quality evidence. 5

Combination of cholestyramine with mesalamine should be avoided because it does not improve outcomes compared with mesalamine alone. Low‑quality evidence. 5, 3
Boswellia serrata is not recommended due to lack of statistically significant benefit and concerns about product standardization. Low‑quality evidence. 3, 6
Probiotics have uncertain benefit and are supported only by low‑quality evidence from small trials; therefore they are not recommended. Low‑quality evidence. 5, 3, 4

Maintenance therapy is indicated only for patients who experience clinical relapse after stopping induction treatment. Conditional recommendation. 5, 3
Approximately one‑third of patients may not require any maintenance therapy. Conditional recommendation. 5
Budesonide 6 mg daily is strongly recommended for maintenance in patients with recurrent symptoms, reducing the risk of relapse by 66 % (relative risk 0.34; 95 % CI 0.19–0.6) over six months. Strong evidence. 5, 3, 4
An alternative maintenance schedule of 3 mg daily alternating with 6 mg daily for 12 months shows comparable efficacy. Moderate evidence. 5, 3
Taper to the lowest effective dose and consider stopping maintenance after 6–12 months if disease remains quiescent. Conditional recommendation. 5

Prolonged budesonide use may increase the risk of osteoporosis despite its low systemic bioavailability; bone health should be monitored. Conditional recommendation. 5
Implement osteoporosis prevention and screening in patients requiring long‑term budesonide maintenance. Conditional recommendation. 5

In corticosteroid‑refractory collagenous colitis, limited case‑series suggest that immunosuppressants (e.g., azathioprine) or anti‑TNF agents may be beneficial. Decisions should be made in consultation with gastroenterology specialists. Very low‑quality evidence. 5